Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

University Health Network, Toronto2 enrolled

Overview

This is an extension study of Protocol CA194002 to allow 2 specific participants with basal cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923 to continue receiving the study drug. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.

The purpose of this study is to evaluate the safety and tolerability of BMS-833923 administered on an extension protocol in subjects with basal cell nevus syndrome (BCNS). This is an extension study of Protocol CA194002 to allow 2 specific participants with BCNS in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923, to continue receiving the study drug. In this open-label extension protocol, no new subjects will be recruited. The two BCNS subjects from Protocol CA194002 (subjects CA194002-1-14 and CA194002-1-25) will continue to receive BMS-833923 at the dose and schedule administered on CA194002 until fulfilling protocol criteria for discontinuation. These patients are receiving different doses: one being 60mg once every 2 weeks, and the other is receiving 300mg once daily. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Basal Cell Nevus Syndrome

Interventions

BMS-833923DRUG

BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed consent * Two specific study participants enrolled on protocol CA194002 at Princess Margaret Cancer Centre and remain on BMS-833923 at the time of study entry * Women, age 18 years and above * Agree to use methods to prevent pregnancy, not pregnant or breastfeeding Exclusion Criteria: * Known symptomatic brain metastasis * A serious uncontrolled medical disorder or active infection, which would impair the ability of the patient to receive protocol therapy * Gastrointestinal disease or surgery that could impact the absorption of study drug * Inability to swallow oral medication * Inability to be venipunctured and/or tolerate venous access * Uncontrolled or significant cardiovascular * Any other medical, psychiatric and/or social reason * Have HIV, HepB, or HepC * Exposure to immunosuppressants and immunotherapy concurrently with study treatment and up to 3 months * Acceptable physical and laboratory test findings * History of allergy to compounds chemically-related

Locations (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Frequency of side effects experienced per participant

Time frame: From date of first study drug dose taken for this study until participant discontinuation, assessed up to 5 years

Secondary Outcomes

Length of time participants' disease does not worsen

Time frame: From date of first study drug dose taken for this study until the date of first documented progression or date of death from any cause, whichever comes first, accessed up to 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.